NEWS & VIEWS

Mediathek

PORTFOLIO
TRENKWALDER

Trenkwalder starts learning platform for companies and candidates

Trenkwalder starts with Trenkwalder Learning a European online marketplace, which provides easy access to training courses for employees.

PORTFOLIO
HAL ALLERGY GROUP

Dr. Tomasz P. Bednarczyk (CCO & CFO) explains the value enhancement through MORE - the Transformation Program of Droege Group.

HAL Allergy uses the established and proven transformation program “MORE” developed by the Droege Group by structuring its operational business within an activity based framework. Dr. Tomasz P. Bednarczyk Chief Commercial & Financial Officer of HAL Allergy Group explains: "Our aim is to achieve the overarching goal of providing the best possible medical products and scientific output in order to increase quality of life for patients in the field of allergy."

Droege Group (founded in 1988) is an independent Advisory and Investment Company. Over 25 years the Group acts with its service program as a specialist for customized restructuring and growth programs aiming at value enhancement. Key philosophy is consistent implementation of change. Droege Group engages with equity in companies and offers the same entrepreneurial approach as a service provider in customized Value-add engagements („Entrepreneurship as a Service“).

Core of the services are the transformation programs "MORE" and "SMART":
MORE represents "Mobilize - Optimize - Reinvent - Enhance" and includes all strategic, operational and financial dimensions of value creation, restructuring and growth initiatives.
SMART represents "Scale - Money - Acceleration - Resources - Time" and is aimed at emerging high growth companies which add to the existing platforms of Droege Group in terms of automation, digitization and mobilization.

PORTFOLIO
HAL ALLERGY GROUP

Dr. Harry Flore (CEO) about HAL Allergy

HAL Allergy is a modern company with high quality pharmaceutical GMP manufacturing and research facilities located in the Leiden Bio Science Park. With offices in seven European countries, we are one of the top European players in the field of allergy diagnostic and treatment. Since 1959 we have gained experience in developing, producing and selling allergy therapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings.

back to top
News & Views Mediathek
close